Physician profile
John A Freeman
NPI 1922199041
$2,396.87
in general payments reported to CMS, 2019-2025
19 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $1,097 · 2021: $118 · 2022: $280 · 2023: $418 · 2024: $101 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.22 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,196.05 | 2019-2025 | Erleada |
| Abbvie INC. | $205.45 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $175.54 | 2023-2025 | Orgovyx |
| Intuitive Surgical, INC. | $123.03 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.07 | 2019-2022 | |
| Boston Scientific Corporation | $85.15 | 2020-2024 | Advantage System, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $82.91 | 2019-2023 | Myrbetriq |
| Accord Healthcare, INC. | $76.05 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $62.74 | 2021-2023 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $55.19 | 2022-2023 | Jelmyto |
| 180 Medical, INC. | $46.20 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $36.65 | 2022 | |
| Allergan, INC. | $29.62 | 2022 | |
| Dendreon Pharmaceuticals LLC | $25.11 | 2020 | |
| Myovant Sciences INC. | $24.74 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.93 | 2021 | |
| Palette Life Sciences, INC. | $22.58 | 2023 | |
| Progenics Pharmaceuticals, INC. | $20.18 | 2023 | Pylarify |
| Amgen INC. | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.